Resistant hypertension, characterized by blood pressure (BP) that remains uncontrolled despite the use of multiple antihypertensive medications, presents a formidable challenge for both patients and clinicians.
However, there is renewed hope with the advent of innovative pharmacologic and device-based approaches that offer the potential for effective and safe treatment. In this article, we delve into the intricacies of diagnosing resistant hypertension, ruling out other conditions, and exploring cutting-edge therapies that hold promise in managing elevated blood pressure.
The Complexity of Resistant Hypertension
Diagnosing and managing resistant hypertension can be a complex task. It is defined as having a BP exceeding 130/80 mm Hg despite a person being prescribed at least three antihypertensive medications. Typically, these medications include an ACE inhibitor or angiotensin receptor blocker, a thiazide diuretic, and a long-acting calcium channel blocker.
Norman E. Lepor, MD, FACC, clinical professor of medicine at the Geffen School of Medicine at UCLA, emphasizes the importance of carefully ruling out other conditions that may mimic resistant hypertension. Conditions such as primary aldosteronism, thyroid disease, obstructive sleep apnea, and rare cases like pheochromocytoma, Cushing’s syndrome, or coarctation of the aorta should be considered during the diagnostic process.
Ruling Out Other Conditions
Proper assessment for factors contributing to resistant hypertension is essential for tailoring the most appropriate treatment plan. Clinicians need to evaluate the patient’s BP correctly and ensure adherence to the recommended classes of medicines. Assessing patient compliance is crucial, as issues such as cost, adverse effects, complex dosing schedules, memory problems, or psychiatric conditions can affect medication adherence.
Additionally, pseudoresistant hypertension, which can result from poor patient-clinician relationships or improper BP measurement techniques, should be ruled out. Employing a 24-hour BP monitor and discussing medication adherence are vital steps in the diagnostic process.
Optimizing Drug Therapies
The American Heart Association’s scientific statement on resistant hypertension recommends adding a mineralocorticoid receptor antagonist (MRA) like spironolactone when BP remains uncontrolled despite the use of renin-angiotensin system blockers, calcium channel blockers, and diuretics. Spironolactone has demonstrated greater effectiveness in reducing BP than other agents in uncontrolled hypertension. However, even with the use of MRAs, a high unmet medical need persists.
Exciting new therapies on the horizon, such as ocedurenone (KBP-5074), a nonsteroidal MRA, aprocitentan (Idorsia), an endothelin receptor antagonist, and IONIS-AGT-LRX (Ionis), an angiotensinogen inhibitor, show great promise in addressing this need.
Emerging Device-based Approaches
Renal denervation has emerged as a potential breakthrough in the management of resistant hypertension. Both radiofrequency and ultrasound renal denervation have shown significant BP-lowering effects over a 24-hour period, without causing long-term renal artery stenosis or worsening renal function. Clinical trials have demonstrated sustained BP reduction for up to 3 years, with a benefit equivalent to that of a single medication. Renal denervation may be a viable option for patients who are unable to tolerate long-term medications or cannot tolerate medications at all, especially those with high cardiovascular risk.
The management of resistant hypertension requires a multifaceted approach. Careful diagnosis, ruling out other conditions, and optimizing drug therapies are crucial steps in achieving effective BP control. The emergence of innovative pharmacologic and device-based approaches provides hope for patients and clinicians alike. With continued research and advancements in treatment options, the outlook for managing resistant hypertension is increasingly optimistic.
